Probiotics in Clostridium difficile infection: Reviewing the need for a multistrain probiotic

Beneficial Microbes

Volumn 4, Issue 1, 2013, Pages 39-51

  Hell, M ^a   Bernhofer, C ^a   Stalzer, P ^a   Kern, J M ^a   Claassen, E ^b,c  

^a UNIVERSITY OF SALZBURG   (Austria)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ATHENA INSTITUTE   (Netherlands)

Author keywords

Clostridium difficile; Colonisation of GI tract; Colonisation resistance; Diarrhoea; Intestinal mucosa

Indexed keywords

CIPROFLOXACIN; ECOLOGIC; METRONIDAZOLE; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; OMNIBIOTIC; PIVMECILLINAM; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL RADIOGRAPHY; ABNORMAL LABORATORY RESULT; ARTICLE; ATOPIC DERMATITIS; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM LONGUM; CASE STUDY; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL STUDY; CLOSTRIDIUM DIFFICILE INFECTION; COMMENSAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG USE; ENTEROCOCCUS FAECIUM; HOMEOSTASIS; HOSPITAL INFECTION; HUMAN; ILEITIS; INFECTION PREVENTION; INFECTIOUS DIARRHEA; INTESTINE FLORA; INTESTINE MUCOSA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS SALIVARIUS; NONHUMAN; RECURRENT INFECTION; REINFECTION; RISK FACTOR; SUBMUCOSA; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 84875261269     PISSN: 18762883     EISSN: 18762891     Source Type: Journal    
DOI: 10.3920/BM2012.0049     Document Type: Article

References (65)

1. Bauer, M.P. and Van Dissel, J.T., 2009. Alternative strategies for Clostridium difficile infection. International Journal of Antimicrobial Agents 33: S51-S56.
2. Bauer, M.P., Kuijper, E.J., Van Dissel, J.T. and European Society of Clinical Microbiology and Infectious Diseases, 2009. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clinical Microbiology and Infection 15: 1067-1079.
3. Borthakur, A., Gill, R.K., Tyagi, S., Koutsouris, A., Alrefai, W.A., Hecht, G.A., Ramaswamy, K. and Dudeja, P.K., 2008. The probiotic Lactobacillus acidophilus stimulates chloride/hydroxyl exchange activity in human intestinal epithelial cells. Journal of Nutrition 138: 1355-1359.
4. Brandt, L.J., 2012. Fecal transplantation for the treatment of Clostridium difficile infection. Gastroenterology and Hepatology of CNY 8: 191-194.
5. Brandtzaeg, P. and Pabst, R., 2004. Let's go mucosal: communication on slippery ground. Trends in Immunology 25: 570-577.
6. Bron, P., A., Van Baarlen, P. and Kleerebezem, M., 2012. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nature Reviews Microbiology 10: 66-78.
7. Cadieux, P.A., Burton, J., Devillard, E. and Reid, G., 2009. Lactobacillus by-products inhibit the growth and virulence of uropathogenic Escherichia coli. Journal of Physiology and Pharmacology 60 Suppl. 6: 13-18.
8. Cartman, S.T., Heap, J.T., Kuehne, S.A., Cockayne, A. and Minton, N.P., 2010. The emergence of 'hypervirulence' in Clostridium difficile. International Journal of Medical Microbiology 300: 387-395.
9. Chapman, C.M., Gibson, G.R. and Rowland, I., 2011. Health benefits of probiotics: are mixtures more effective than single strains? European Journal of Nutrition 50:1-17.
10. Chinen, T. and Rudensky, A.Y., 2012. The effects of commensal microbiota on immune cell subsets and inflammatory responses. Immunological Reviews 245: 45-55.
11. Cohen, S.H., Gerding, D.N., Johnson, S., Kelly, C.P., Loo, V.G., McDonald, L.C., Pepin, J., Wilcox, M.H., the Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America, 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology 31: 431-455.
12. De Vuyst, L., Vrancken, G., Ravyts, F., Rimaux, T. and Weckx, S., 2009. Biodiversity, ecological determinants, and metabolic exploitation of sourdough microbiota. Food Microbiology 26: 666-675.
13. Dean, P., Maresca, M., Schuller, S., Phillips, A.D. and Kenny, B., 2006. Potent diarrheagenic mechanism mediated by the cooperative action of three enteropathogenic Escherichia coli-injected effector proteins. Proceedings of the National Academy of Sciences of the USA 103: 1876-1881.
14. Dockray, G.J., 2003. Luminal sensing in the gut: an overview. Journal of Physiology and Pharmacology 54 Suppl. 4: 9-17.
15. Ege, M.J., Mayer, M., Normand, A.C., Genuneit, J., Cookson, W.O., Braun-Fahrlander, C., Heederik, D., Piarroux, R. and Von Mutius, E. for the GABRIELA Transregio 22 Study Group, 2011. Exposure to environmental microorganisms and childhood asthma. New England Journal of Medicine 364: 701-709.
16. Feleszko, W., Jaworska, J. and Hamelmann, E., 2006. Toll-like receptors - novel targets in allergic airway disease (probiotics, friends and relatives). European Journal of Pharmacology 533: 308-318.
17. Floch, M.H., Walker, W.A., Madsen, K., Sanders, M.E., Macfarlane, G.T., Flint, H.J., Dieleman, L.A., Ringel, Y., Guandalini, S., Kelly, C.P. and Brandt, L.J., 2011. Recommendations for probiotic use - 2011 update. Journal of Clinical Gastroenterology 45 Suppl.: S168-S171.
18. Guarner, F., Bourdet-Sicard, R., Brandtzaeg, P., Gill, H.S., McGuirk, P., Van Eden, W., Versalovic, J., Weinstock, J.V. and Rook, G.A., 2006. Mechanisms of disease: the hygiene hypothesis revisited. Nature Clinical Practice: Gastroenterology & Hepatology 3: 275-284.
19. Hall, I.C. and O'Toole, E., 1935. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficile. American Journal of Diseases in Childhood 49: 390-402.
20. Hautmann, M.G., Hipp, M. and Kolbl, O., 2011. Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment? Radiation Oncology 6: 89.
21. Hayashi, H., Szaszi, K., Coady-Osberg, N., Furuya, W., Bretscher, A.P., Orlowski, J. and Grinstein, S., 2004. Inhibition and redistribution of NHE3, the apical Na+/H+ exchanger, by Clostridium difficile toxin B. Journal of General Physiology 123: 491-504.
22. Hell, M., Permoser, M., Chmelizek, G., Kern, J.M., Maass, M., Huhulescu, S., Indra, A. and Allerberger, F., 2011. Clostridium difficile infection: monoclonal or polyclonal genesis? Infection 39: 461-465.
23. Hell, M., Sickau, K., Chmelizek, G., Kern, J.M., Maass, M., Huhulescu, S. and Allerberger, F., 2012. Absence of Clostridium difficile in asymptomatic hospital staff. American Journal of Infection Control 40: 1023-1024.
24. Hempel, S., Newberry, S.J., Maher, A.R., Wang, Z., Miles, J.N., Shanman, R., Johnsen, B. and Shekelle, P.G., 2012. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. Journal of the American Medical Association 307: 1959-1969.
25. Heuvelin, E., Lebreton, C., Bichara, M., Cerf-Bensussan, N. and Heyman, M., 2010. A Bifidobacterium probiotic strain and its soluble factors alleviate chloride secretion by human intestinal epithelial cells. Journal of Nutrition 140: 7-11.
26. Hickson, M., 2011. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therapeutic Advances in Gastroenterology 4: 185-197.
27. Hodges, K. and Gill, R., 2010. Infectious diarrhea: cellular and molecular mechanisms. Gut Microbes 1: 4-21.
28. Ishihara, E., Nagahama, M., Naruse, S., Semba, R., Miura, T., Usami, M. and Narita, M., 2008. Neuropathological alteration of aquaporin 1 immunoreactive enteric neurons in the streptozotocin-induced diabetic rats. Autonomic Neuroscience 138: 31-40.
29. Islam, J., Cohen, J., Rajkumar, C. and Llewelyn, M.J., 2012. Probiotics for the prevention and treatment of Clostridium difficile in older patients. Age and Ageing 41: 706-711.
30. Johnston, B.C., Ma, S.S., Goldenberg, J.Z., Thorlund, K., Vandvik, P.O., Loeb, M. and Guyatt, G.H., 2012. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Annals of Internal Medicine 157: 878-888.
31. Karczewski, J., Troost, F.J., Konings, I., Dekker, J., Kleerebezem, M., Brummer, R.J. and Wells, J.M., 2010. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. American Journal of Physiology - Gastrointestinal and Liver Physiology 298: G851-859.
32. Kelly, C.P., 2009. A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection. Journal of the American Medical Association 301: 954-962.
33. Kelly, G., 2008. Inulin-type prebiotics - a review: part 1. Alternative Medicine Review 13: 315-329.
34. Kyne, L., Warny, M., Qamar, A. and Kelly, C.P., 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. New England Journal of Medicine 342: 390-397.
35. Louie, T.J., Cannon, K., Byrne, B., Emery, J., Ward, L., Eyben, M. and Krulicki, W., 2012. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clinical Infectious Diseases 55 Suppl. 2: S132-142.
36. Malaguarnera, G., Leggio, F., Vacante, M., Motta, M., Giordano, M., Bondi, A., Basile, F., Mastrojeni, S., Mistretta, A., Malaguarnera, M., Toscano, M.A. and Salmeri, M., 2012. Probiotics in the gastrointestinal diseases of the elderly. The Journal of Nutrition, Health and Aging 16: 402-410.
37. Malakooti, J., Saksena, S., Gill, R.K. and Dudeja, P.K., 2011. Transcriptional regulation of the intestinal luminal Na(+) and Cl(-) transporters. Biochemical Journal 435: 313-325.
38. McFarland, L.V., 2011. Emerging therapies for Clostridium difficile infections. Expert Opinion in Emerging Drugs 16: 425-439.
39. Mercenier, A., Muller-Alouf, H. and Grangette, C., 2000. Lactic acid bacteria as live vaccines. Current Issues in Molecular Biology 2: 17-25.
40. Morishima, T., Aoyama, M., Iida, Y., Yamamoto, N., Hirate, H., Arima, H., Fujita, Y., Sasano, H., Tsuda, T., Katsuya, H., Asai, K. and Sobue, K., 2008. Lactic acid increases aquaporin 4 expression on the cell membrane of cultured rat astrocytes. Neuroscience Research 61: 18-26.
41. Morrow, L.E., Gogineni, V. and Malesker, M.A., 2012. Probiotic, prebiotic, and symbiotic use in critically ill patients. Current Opinion in Critical Care 18: 186-191.
42. Moudgal, V. and Sobel, J.D., 2012. Clostridium difficile colitis: a review. Hospital Practice 40: 139-148.
43. Nakatsuji, T. and Gallo, R.L., 2012. Antimicrobial peptides: old molecules with new ideas. Journal of Investigative Dermatology 132: 887-895.
44. Nguyen, C.A., Akiba, Y. and Kaunitz, J.D., 2012. Recent advances in gut nutrient chemosensing. Current Medicinal Chemistry 19: 28-34.
45. Ohland, C.L., DeVinney, R. and MacNaughton, W.K., 2012. Escherichia coli-induced epithelial hyporesponsiveness to secretagogues is associated with altered CFTR localization. Cellular Microbiology 14: 447-459.
46. Olive, C., 2012. Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants. Expert Review of Vaccines 11: 237-256.
47. Parkes, G.C., Sanderson, J.D. and Whelan, K., 2009. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. Lancet Infectious Diseases 9: 237-244.
48. Rousseaux, C., Thuru, X., Gelot, A., Barnich, N., Neut, C., Dubuquoy, L., Dubuquoy, C., Merour, E., Geboes, K., Chamaillard, M., Ouwehand, A., Leyer, G., Carcano, D., Colombel, J.F., Ardid, D. and Desreumaux, P., 2007. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nature Medicine 13: 35-37.
49. Saadoun, S. and Papadopoulos, M.C., 2010. Aquaporin-4 in brain and spinal cord oedema. Neuroscience 168: 1036-1046.
50. Salzman, N.H., Underwood, M.A. and Bevins, C.L., 2007. Paneth cells, defensins, and the commensal microbiotal: a hypothesis on intimate interplay at the intestinal mucosa. Seminars in Immunology 19: 70-83.
51. Sherman, P.M., Ossa, J.C. and Johnson-Henry, K., 2009. Unraveling mechanisms of action of probiotics. Nutrition in Clinical Practice 24: 10-14.
52. Singla, A., Kumar, A., Priyamvada, S., Tahniyath, M., Saksena, S., Gill, R.K., Alrefai, W.A. and Dudeja, P.K., 2012. LPA stimulates intestinal DRA gene transcription via LPA2 receptor, PI3K/AKT, and c-Fos-dependent pathway. American Journal of Physiology -Gastrointestinal and Liver Physiology 302: G618-G627.
53. Swartz, T.D., Duca, F.A., De Wouters, T., Sakar, Y. and Covasa, M., 2012. Up-regulation of intestinal type 1 taste receptor 3 and sodium glucose luminal transporter-1 expression and increased sucrose intake in mice lacking gut microbiota. British Journal of Nutrition 107: 621-630.
54. Tschudin-Sutter, S., Widmer, A.F. and Perl, T.M., 2012. Clostridium difficile: novel insights on an incessantly challenging disease. Current Opinion in Infectious Diseases 25: 405-411.
55. Ulluwishewa, D., Anderson, R.C., McNabb, W.C., Moughan, P.J., Wells, J.M. and Roy, N.C., 2011. Regulation of tight junction permeability by intestinal bacteria and dietary components. Journal of Nutrition 141: 769-776.
56. Van Baarlen, P., Troost, F., Van der Meer, C., Hooiveld, G., Boekschoten, M., Brummer, R.J.M. and Kleerebezem, M., 2011. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proceedings of the National Academy of Sciences of the USA 108 Suppl. 1: 4562-4569.
57. Van Baarlen, P., Troost, F., Van Hemert, S., Van der Meer, C., De Vos, W.M., De Groot, P.J., Hooiveld, G.J.E.J., Brummer, R.J.M. and Kleerebezem, M., 2009. Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proceedings of the National Academy of Sciences of the USA 106: 2371-2376.
58. Van Driel, I.R. and Ang, D.K., 2008. Role of regulatory T cells in gastrointestinal inflammatory disease. Journal of Gastroenterology and Hepatology 23: 171-177.
59. Van Huynegem, K., Loos, M. and Steidler, L., 2009. Immunomodulation by genetically engineered lactic acid bacteria. Frontiers in Bioscience 14: 4825-4835.
60. Van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E.G., De Vos, W.M., Visser, C.E., Kuijper, E.J., Bartelsman, J.F., Tijssen, J.G., Speelman, P., Dijkgraaf, M.G. and Keller, J.J., 2013. Duodenal infusion of donor feces for recurrent Clostridium difficile. New England Journal of Medicine 368: 407-415.
61. Verna, E.C. and Lucak, S., 2010. Use of probiotics in gastrointestinal disorders: what to recommend? Therapeutic Advances in Gastroenterology 3: 307-319.
62. Veshnyakova, A., Piontek, J., Protze, J., Waziri, N., Heise, I. and Krause, G., 2012. Mechanism of Clostridium perfringens enterotoxin interaction with claudin-3/-4 protein suggests structural modifications of the toxin to target specific claudins. Journal of Biological Chemistry 287: 1698-1708.
63. Videlock, E.J. and Cremonini, F., 2012. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Alimentary Pharmacology and Therapeutics 35: 1355-1369.
64. Wells, J.M., 2011. Immunomodulatory mechanisms of lactobacilli. Microbial Cell Factories 10 Suppl. 1: S17.
65. Wolvers, D., Antoine, J.M., Myllyluoma, E., Schrezenmeir, J., Szajewska, H. and Rijkers, G.T., 2010. Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics. Journal of Nutrition 140: 698S-712S.